A Review on Signal in Pharmacovigilance

Authors

  • Ritu Rani College of Pharmacy, Roorkee Uttarakhand, India
  • Subhash Chand College of Pharmacy, Roorkee Uttarakhand, India
  • Arjun Singh College of Pharmacy, Roorkee Uttarakhand, India
  • Deovrat Kumar College of Pharmacy, Roorkee Uttarakhand, India
  • Meena Devi College of Pharmacy, Roorkee Uttarakhand, India

DOI:

https://doi.org/10.22270/ajprd.v7i6.591

Keywords:

Signal, Pharmacovigilance, Adverse drug reaction, Signal detection, Signal strengthening.

Abstract

A safety signal is data or information that may suggest a new causal association, or contribute new information about a known association, between a medicine and an adverse event that justifies further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. Signal is a potential medicine safety issues, which are derived from individual case safety reports in vigiBase. Signal detection is a cornerstone of drug development process ensuring drug safety. The early detection of Signals helps to improve patient safety and reduce economic burden due to escalating cost of medications and unwanted adverse effects associated with it. The present study is an initiative to make significant contribution towards health-care system by generating evidence based data to benefit health care professionals, consumers, pharmaceutical companies and regulatory authorities.Signal detection and signal strengthening is the most important aspect in Pharmacovigilance which plays an important role in ensuring that patients receive safe drugs. For detection of adverse drug reactions, clinical trials usually provide limited information as they are conducted under strictly controlled conditions. Some of the adverse drug reaction can be detected only after long term use in larger population and in specific patient groups due to specific concomitant medications or disease.

 

Downloads

Download data is not yet available.

Author Biographies

Ritu Rani, College of Pharmacy, Roorkee Uttarakhand, India

College of Pharmacy, Roorkee Uttarakhand, India

Subhash Chand, College of Pharmacy, Roorkee Uttarakhand, India

College of Pharmacy, Roorkee Uttarakhand, India

Arjun Singh, College of Pharmacy, Roorkee Uttarakhand, India

College of Pharmacy, Roorkee Uttarakhand, India

Deovrat Kumar, College of Pharmacy, Roorkee Uttarakhand, India

College of Pharmacy, Roorkee Uttarakhand, India

Meena Devi, College of Pharmacy, Roorkee Uttarakhand, India

College of Pharmacy, Roorkee Uttarakhand, India

References

1. Thota P, Thota A, Medhi B, Sidhu S, Kumar P, Selvan VK, Singh GN. Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India. Perspectives in clinical research. 2018; 9(1):51.
2. World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. Geneva: World Health Organization; 2004.
3. Zhengwu Lu. Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives: Drug, Healthcare and patient Safety. 2009; 135-45.
4. World Health Organization: The importance of Pharmacovigilance Safety Monitoring of Medicinal products: 2002.
5. Prakash S. Pharmacovigilance in India. Indian Journal of Pharmacology. 2007; 39(3).
6. Zhengwu Lu. Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives: Drug, Healthcare and patient Safety. 2009; 135-45.
7. ADRs reporting systems and signal detection. Viewpoint, Part 2, the Uppsala Monitoring Centre. 2005
8. Edwards IR, Aronson JK (2000) adverse drug reactions: Definitions, diagnosis, and management. Lancet 356:1255
9. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of internal medicine. 2004; 140(10):795-801.
10. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharm 2007; 7:1-5.
11. Chakraborty BS. Pharmacovigilance: A data mining approach to signal detection. Indian journal of pharmacology. 2015; 47(3):241.
12. World Health Organization (WHO) guidelines on safety monitoring of herbal medicines in pharmacovigilance systems, World Health Organization, Geneva: WHO 2004.
13. Chakraborty BS. Pharmacovigilance: A data mining approach to signal detection. Indian journal of pharmacology. 2015; 47(3):241.
14. ADRs reporting systems and signal detection. Viewpoint, Part 2, the Uppsala Monitoring Centre. 2005.
15. Mubasheera Mg, Pharmacovigilance (PV) continue signal detection, Department of Pharmacy, Nov-20, 2007.
16. ADRs reporting systems and signal detection. Viewpoint, Part 2, the Uppsala Monitoring Centre. 2005
17. Kumar anoop, Khan Henna, Signal detection and their assessment in Pharmacovigilance, Departmental of pharmaceutical science. Open pharmaceutical science journal, 2015; 2:66-73.
18. S.K Gupta, Signal detection in Pharmacovigilance, A textbook of Pharmacovigilance, 2011:- 60-74.
19. Ronald H.B. Meyboom,1,2,3 Marie Lindquist,1 Antoine C.G. Egberts 2,4 and I. Ralph Edwards, Signal Selection and Follow-Up in Pharmacovigilance, Drug Safety 2002; 459-465.
20. CIOMS working Group. Practical aspects of signal detection in pharmacovigilance. Geneva; 2010(8).

Published

2019-12-15

How to Cite

Rani, R., Chand, S., Singh, A., Kumar, D., & Devi, M. (2019). A Review on Signal in Pharmacovigilance. Asian Journal of Pharmaceutical Research and Development, 7(6), 80–84. https://doi.org/10.22270/ajprd.v7i6.591